Veterinary Pharmaceuticals Market Report 2026-2031, By Product, Route of Administration, and Geo

Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User�Global Forecast to 2031

$28.98B

MARKET SIZE, 2026

$39.37B

MARKET SIZE, 2031

6.3%

CAGR (2026-2031)

2026-2031

FORECAST PERIOD

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global veterinary pharmaceuticals market, valued at USD 27.41 billion in 2025, stood at USD 28.98 billion in 2026 and is projected to advance at a resilient CAGR of 6.3% from 2026 to 2031, culminating in a forecasted valuation of USD 39.37 billion by the end of the period. The market growth is driven by rising pet ownership, increasing livestock production, and higher demand for disease management drugs. Expanding awareness of animal health, growing expenditure on companion animals, and advancements in anti-infectives, parasiticides, and dermatology treatments are further supporting steady market expansion across developed and emerging regions.

KEY TAKEAWAYS

MARKET SNAPSHOT:
Base Year Market Size (2025): USD 27.41 Billion
Current Market Size (2026): USD 28.98 Billion
Forecast Market Size (2031): USD 39.37 Billion
CAGR (2026�2031): 6.3%
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest market share of 38.4% in 2025.
Product Leader: Monoclonal antibodies are projected to witness the highest CAGR of 7.3% during the forecast period.
Route of Administration Leader: Oral accounted for the largest market share of 48.2% in 2025.
Formulation Leader: Solid formulation commanded a 40.2% market share in 2025.
Indication Leader: Dermatological diseases are expected to register the highest growth rate of 8.6% during the forecast period.
Animal Type Leader: Companion animals are projected to witness the highest CAGR of 8.0% during the forecast period.
Distribution Channel Leader: Veterinary hospital pharmacies accounted for the largest market share of 65.5%.
End User Leader: Veterinary hospitals & clinics are projected to register the highest growth rate of 7.9%.
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Zoetis Inc. (US) and Boehringer Ingelheim Animal Health (Germany) stand out as star players because of their strong regional footprint, established product portfolios, and consistent leadership in veterinary pharmaceutical products.
Phibro Animal Health Corporation (US) and Chanelle Pharma (Ireland) are emerging players due to expanding portfolios, broader global reach, and a strong focus on niche and cost-effective veterinary therapeutics.

The market offers robust opportunities in emerging countries, where livestock numbers are increasing, and veterinary infrastructure is being developed. The rise in pet humanization in the Asia Pacific and Latin American regions is creating opportunities for high-quality drugs and treatments for chronic diseases. The development of e-commerce veterinary pharmacies and tele-veterinary care also contributes to the availability of drugs. Moreover, advancements in long-acting formulations, combination drugs, and species-specific drugs are creating new avenues for pharmaceutical companies.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The veterinary pharmaceuticals market is undergoing a paradigm shift due to regulations related to antimicrobial resistance, the humanization of companion animals, and the need for productivity in farm animal production. Traditional antimicrobials and generics are slowly being replaced by innovative biologics, long-acting products, and precision medicines. This shift has created a new set of client needs, driving the development of preventive medicine and altering the animal health, farm economics, and public health infrastructure landscape.

veterinary-pharmaceuticals-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers

Impact
Level

Rising companion animal ownership and pet humanization
Increasing prevalence of infectious and dermatological diseases in animals

RESTRAINTS

Impact
Level

Growing concerns over antimicrobial resistance (AMR)
Stringent regulatory approval processes for veterinary drugs

OPPORTUNITIES

Impact
Level

Rising demand for parasiticides and dermatology products
Growth potential in rural and low-income regions

CHALLENGES

Impact
Level

Monitoring drug residues in food-producing animals
Balancing animal welfare, productivity, and compliance requirements

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising companion animal ownership and pet humanization

The steady rise in companion animal ownership, particularly in urban areas, is driving significant demand for veterinary pharmaceuticals. Pets are increasingly viewed as family members, leading to higher spending on preventive and therapeutic care. Owners are willing to invest in advanced treatments for chronic conditions such as dermatological disorders, arthritis, and infections. This humanization trend is expanding demand for premium, specialty, and long-term pharmaceutical products in the companion animal segment.

Restraint: Growing concerns over antimicrobial resistance (AMR)

The rising threat of antimicrobial resistance is restricting the use of antibiotics in veterinary practice, especially in food-producing animals. Regulatory authorities are tightening guidelines on antibiotic use to prevent cross-resistance that could affect human health. This limits routine prophylactic use and increases manufacturers' compliance costs. Additionally, reduced antibiotic consumption in livestock directly impacts revenue from anti-infective drug segments within the veterinary pharmaceuticals market.

Opportunity: Rising demand for parasiticides and dermatology products

Parasiticides and dermatology drugs represent a strong growth opportunity due to the high prevalence of ectoparasites, endoparasites, and skin disorders in both companion and livestock animals. Increasing awareness about preventive healthcare, tick and flea control, and zoonotic disease risks is boosting product adoption. Long-acting topical, oral, and combination therapies are gaining traction, creating expansion opportunities for manufacturers focused on innovative and broad-spectrum formulations.

Challenge: Monitoring drug residues in food-producing animals

Ensuring compliance with maximum residue limits (MRLs) in meat, milk, and eggs remains a major challenge for pharmaceutical manufacturers and livestock producers. Strict international trade regulations require rigorous monitoring of drug withdrawal periods and residue testing. Non-compliance can lead to export bans, recalls, and reputational damage. This increases the need for pharmacovigilance, traceability systems, and responsible drug administration practices in food-producing animal sectors.

VETERINARY PHARMACEUTICALS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Develops and commercializes a broad portfolio of veterinary pharmaceuticals across anti-infectives, parasiticides, dermatology, pain management, and specialty care for companion and livestock animals. Utilizes long-acting formulations, chewable tablets, and injectable therapies to improve compliance.	Improves treatment adherence through palatable and extended-duration formulations, enhances animal welfare outcomes, supports herd productivity, and drives preventive care adoption in companion animals.
	Provides integrated pharmaceutical solutions including anti-parasitics, anti-infectives, reproductive health drugs, and metabolic disorder treatments, supported by digital monitoring and herd management platforms.	Enables data-driven disease management, improves farm-level productivity, reduces economic losses from infectious diseases, and strengthens preventive health programs.
	Focuses on innovative parasiticides, respiratory and enteric disease treatments, and specialty therapeutics for companion animals, backed by strong R&D and species-specific drug formulations.	Delivers high-efficacy treatments with strong safety profiles, enhances disease control in intensive livestock systems, and supports premium companion animal healthcare growth.
	Offers diversified veterinary pharmaceuticals targeting dermatological diseases, parasitic infections, pain, and gastrointestinal disorders, with emphasis on sustainable production animal health solutions.	Promotes antimicrobial stewardship, improves livestock feed efficiency, enhances dermatology treatment outcomes in pets, and aligns with tightening regulatory standards.
	Specializes in dermatology, parasiticides, dental-related pharmaceuticals, and reproductive health treatments for companion and production animals.	Captures high-growth dermatology and parasiticide segments, improves owner compliance via convenient dosage forms, and expands access to advanced veterinary therapeutics globally.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The ecosystem for the veterinary pharmaceuticals market includes global animal health firms, generic pharmaceutical firms, contract research and manufacturing organizations (CRO/CMOs), veterinary hospitals and clinics, animal producers, and government institutions. The development stage is fueled by R&D and species-specific formulations, while the commercialization stage is fueled by robust distribution channels and veterinary partnerships. Government regulations, antimicrobial use, and pet ownership are market drivers.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

By Product Type

The monoclonal antibodies segment is expected to register the highest growth in the veterinary pharmaceuticals market. This is due to the increasing demand for targeted and long-acting therapies, especially in the pet segment. The rising incidence of chronic diseases such as atopic dermatitis, osteoarthritis pain, and inflammatory conditions is driving the demand for mAbs. They offer high specificity, reduced side effects, and improved patient compliance, thanks to the extended dosing interval. Heavy R&D spending, a strong biologics pipeline, and the premiumization of pet healthcare are further fueling this segment's growth.

By Indications

The dermatological conditions segment is expected to dominate the global veterinary pharmaceuticals market by market share in 2025, driven by the high prevalence of skin disorders in both companion and production animals. Conditions such as atopic dermatitis, parasitic infestations, fungal infections, and bacterial skin diseases are frequently diagnosed and require long-term treatment. Rising pet ownership, increasing awareness of animal hygiene, and growing demand for anti-parasitic, antifungal, and anti-inflammatory therapies are key factors supporting the segment’s leading position.

REGION

By Region

North America accounted for the largest share of the global veterinary pharmaceuticals market in 2025, supported by high pet ownership and strong spending on animal healthcare. The region benefits from advanced veterinary infrastructure, widespread insurance coverage for companion animals, and early adoption of premium therapeutics, including biologics and specialty drugs. In addition, the presence of major animal health companies, strong R&D activity, and stringent disease-control programs in livestock production further reinforce the region's market dominance.

veterinary-pharmaceuticals-market Region

VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX

In the company evaluation matrix, Zoetis is positioned as a star player due to its strong global presence, broad pharmaceutical portfolio, and sustained investment in R&D and lifecycle management. The company demonstrates high revenue share, diversified species coverage, and consistent innovation across therapeutic areas. In contrast, Bimeda is categorized as an emerging player, reflecting its expanding geographic footprint, focused product strategy, and growing presence in generics and niche animal health segments.

veterinary-pharmaceuticals-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

Zoetis Inc. (U.S.)
Merck Animal Health (U.S.)
Boehringer Ingelheim Animal Health (Germany)
Elanco (U.S.)
Virbac (France)
Ceva (France)
Vetoquinol (France)
Dechra Pharmaceuticals (U.K.)
Norbrook (U.K.)
Bimeda (Ireland)
Hester Biosciences Limited (India)
Indian Immunologicals Ltd. (India)
Animalcare Group (U.K.)
Kyoritsu Seiyaku (Japan)
Calier (Spain)

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size in 2025 (Value)	USD 27.41 BN
Market Size in 2031 (Value)	USD 39.37 BN
CAGR	GAGR of 6.3% from 2026-2031
Years Considered	2024–2031
Base Year	2025
Forecast Period	2026–2031
Units Considered	Value (USD Bn/Mn), Volume (Thousands Unit)
Report Coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered	By Product Type: Drugs (Anti-Bacterial Drugs, Anti-Fungal Drugs, Anti-Viral Drugs, Anti-Inflammatory Drugs, Anti-Parasitic Drugs, Anticancer Drugs, Cardiovascular And Renal Drugs, Gastrointestinal Drugs, Other Drugs), Monoclonal Antibodies, Immunomodulators, Medicated Feed Additives (Amino Acids, Enzymes, Minerals And Vitamins) I By Route of Administration: Oral, Parenteral, Topical, Other Route Of Administration I By Formulation Type: Solid, Liquid, Semi-Solid, Aerosol, Premix Formulations I By Indications: Infectious Diseases, Dermatological Diseases, Pain Management, Cardiovascular And Renal Diseases, Gastrointestinal Diseases, Other Indications I By Animals: Companion Animals (Dogs, Cats, Horses, Other Companion Animals), Livestock Animals (Cattle, Swine, Poultry, Other Livestock Animals) I By Distribution Challen: Veterinary Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales I By End Users: Veterinary Hospitals & Clinics, Livestock Farms, Home Care Settings, Other End Users
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East and Africa

WHAT IS IN IT FOR YOU: VETERINARY PHARMACEUTICALS MARKET REPORT CONTENT GUIDE

veterinary-pharmaceuticals-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Product Analysis	Assessed key veterinary drug categories including anti-infectives, parasiticides (endo- and ecto-), dermatology drugs, NSAIDs, hormonal products, and feed additives. Evaluated dosage forms such as oral, injectable, topical, and medicated feed. Analyzed product performance, regulatory pathways, withdrawal periods, and innovation trends across companion and livestock segments.	Helped clients prioritize high-growth therapeutic areas such as dermatology and parasiticides. Supported lifecycle planning for generic and branded products. Identified long-acting formulations and combination therapies gaining traction in companion and production animal markets.
Company Information	Profiled major global and regional veterinary pharmaceutical players, covering portfolios, manufacturing footprint, distribution networks, and R&D focus. Assessed strengths in companion animal and livestock therapeutics, including parasiticides and anti-infectives. Reviewed partnerships, acquisitions, and pipeline developments shaping competitive positioning.	Enabled benchmarking of competitive positioning across therapeutic categories and regions. Supported identification of licensing, contract manufacturing, and co-marketing opportunities. Strengthened go-to-market and expansion strategies in regulated and emerging veterinary markets.
Geographic Analysis	Examined veterinary pharmaceutical demand across North America, Europe, Asia-Pacific, and Latin America. Analyzed regulatory frameworks, antimicrobial stewardship policies, livestock demographics, pet ownership growth, and veterinary care infrastructure. Included reimbursement, pricing dynamics, and country-level customization where required.	Supported strategic market entry by identifying high-growth countries and species-specific demand pockets. Helped assess the impact of AMR regulations, residue monitoring norms, and pet humanization trends on long-term revenue potential.

RECENT DEVELOPMENTS

October 2025 : Zoetis (US) received approval in Canada for Leniva, a long-acting monoclonal antibody for canine osteoarthritis pain. Administered once every three months, the product strengthens Zoetis’ companion animal pain portfolio and supports demand for durable biologic therapies in veterinary medicine
July 2025 : Merck & Co. Inc. (US) obtained U.S. FDA approval for BRAVECTO QUANTUM, a once-yearly injectable parasiticide for dogs targeting fleas and ticks. The extended-duration therapy improves treatment compliance and reinforces Merck’s leadership in preventive parasiticides for companion animals
July 2024 : Merck & Co. Inc. (US) completed the USD 1.29 billion acquisition of Elanco’s aquaculture business. The deal added vaccines, medicines, and nutritional products for aquatic species, expanding Merck’s footprint in aquaculture and strengthening its diversified livestock health portfolio
September 2024 : Boehringer Ingelheim (Germany) acquired Saiba Animal Health AG (Switzerland) to enhance its pet therapeutics pipeline. The acquisition added novel chronic disease vaccine technologies, strengthening its biologics research capabilities and supporting innovation in advanced treatments for companion animals

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE

PAGE NO

INTRODUCTION

EXECUTIVE SUMMARY

PREMIUM INSIGHTS

MARKET OVERVIEW

Pet ownership surge and disease prevalence drive veterinary market growth amid regulatory challenges.

4.1

INTRODUCTION

4.2

MARKET DYNAMICS

4.2.1

DRIVERS

4.2.1.1

RISING COMPANION ANIMAL OWNERSHIP AND PET HUMANIZATION

4.2.1.2

GROWING PREVALENCE OF INFECTIOUS AND DERMATOLOGICAL DISEASES IN ANIMALS

4.2.1.3

INCREASING DEMAND FOR ANIMAL-DERIVED FOOD PRODUCTS

4.2.2

RESTRAINTS

4.2.2.1

GROWING CONCERNS OVER ANTIMICROBIAL RESISTANCE (AMR)

4.2.2.2

STRINGENT REGULATORY APPROVAL PROCESSES FOR VETERINARY DRUGS

4.2.3

OPPORTUNITIES

4.2.3.1

RISING DEMAND FOR PARASITICIDES AND DERMATOLOGY PRODUCTS

4.2.3.2

GROWTH POTENTIAL IN RURAL AND LOW-INCOME REGIONS

4.2.4

CHALLENGES

4.2.4.1

MONITORING DRUG RESIDUES IN FOOD-PRODUCING ANIMALS

4.2.4.2

BALANCING ANIMAL WELFARE, PRODUCTIVITY, AND COMPLIANCE REQUIREMENTS

4.3

UNMET NEEDS AND WHITE SPACES

4.4

INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES

4.4.1

INTERCONNECTED MARKETS

4.4.2

CROSS-SECTOR OPPORTUNITIES

4.5

STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

INDUSTRY TRENDS

Navigate competitive dynamics and pricing trends shaping the future of global animal healthcare.

5.1

PORTER’S FIVE FORCES ANALYSIS

5.1.1

THREAT OF NEW ENTRANTS

5.1.2

THREAT OF SUBSTITUTES

5.1.3

BARGAINING POWER OF SUPPLIERS

5.1.4

BARGAINING POWER OF BUYERS

5.1.5

INTENSITY OF COMPETITIVE RIVALRY

5.2

MACROECONOMICS INDICATORS

5.2.1

INTRODUCTION

5.2.2

GDP TRENDS AND FORECAST

5.2.3

TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY

5.2.4

TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY

5.3

VALUE CHAIN ANALYSIS

5.4

SUPPLY CHAIN ANALYSIS

5.5

ECOSYSTEM ANALYSIS

5.6

PRICING ANALYSIS

5.6.1

AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025

5.6.2

AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025

5.6.3

AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025

5.7

TRADE ANALYSIS

5.7.1

IMPORT DATA FOR HS CODE 30, 2021–2024

5.7.1.1

IMPORT SCENARIO (HS CODE 30)

5.7.2

EXPORT DATA FOR HS CODE 30, 2021–2024

5.7.3

EXPORT SCENARIO (HS CODE 30)

5.8

KEY CONFERENCES AND EVENTS IN 2026–2027

5.9

TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.10

INVESTMENT AND FUNDING SCENARIO

5.11

CASE STUDY ANALYSIS

5.11.1

ZOETIS INC.

5.11.2

BOEHRINGER INGELHEIM ANIMAL HEALTH

5.11.3

MERCK ANIMAL HEALTH

5.11.4

ELANCO ANIMAL HEALTH

5.11.5

CEVA SANTE ANIMALE

5.12

IMPACT OF 2025 US TARIFF - VETERINARY PHARMACEUTICALS MARKET

5.12.1

INTRODUCTION

5.12.2

KEY TARIFF RATES

5.12.3

PRICE IMPACT ANALYSIS

5.12.4

IMPACT ON REGIONS

5.12.4.1

NORTH AMERICA

5.12.4.2

EUROPE

5.12.4.3

ASIA PACIFIC

5.12.5

IMPACT ON END-USE INDUSTRIES

5.12.5.1

VETERINARY HOSPITALS & CLINICS

5.12.5.2

HOME CARE SETTINGS

5.12.5.3

LIVESTOCK FARMS

5.12.5.4

RESCUE CENTERS & NGOS

5.12.5.5

OTHER END USERS

TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

AI-driven innovations revolutionize veterinary health with precision management and cutting-edge patent developments.

6.1

TECHNOLOGY ANALYSIS

6.1.1

KEY EMERGING TECHNOLOGIES

6.1.1.1

CONTROLLED RELEASE FORMULATION

6.1.1.2

BIOLOGICS AND MONOCLONAL ANTIBODIES

6.1.2

COMPLEMENTARY TECHNOLOGIES

6.1.2.1

DIGITAL HEALTH AND TELEMEDICINE PLATFORMS

6.1.2.2

VETERINARY BIOMARKER ANALYSIS

6.1.3

ADJACENT TECHNOLOGIES

6.1.3.1

WEARABLE ANIMAL HEALTH MONITORING DEVICES

6.1.3.2

STEM CELL THERAPY AND REGENERATIVE MEDICINE

6.2

TECHNOLOGY/PRODUCT ROADMAP

6.3

PATENT ANALYSIS

6.3.1

PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS

6.3.2

INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015–DECEMBER 2025

6.3.3

LIST OF MAJOR PATENTS, 2023–2025

6.4

FUTURE APPLICATIONS

6.4.1

PRECISION LIVESTOCK HEALTH MANAGEMENT

6.4.2

ONCOLOGY AND CHRONIC DISEASE MANAGEMENT

6.4.3

REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK

6.4.4

INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL

6.5

IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET

REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

Navigate complex regulations and embrace sustainable innovations in veterinary pharmaceuticals globally.

7.1

REGIONAL REGULATIONS AND COMPLIANCE

7.1.1

REGULATORY FRAMEWORK

7.1.1.1

NORTH AMERICA

7.1.1.2

EUROPE

7.1.2

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

7.1.3

INDUSTRY STANDARDS

7.1.3.1

VICH GUIDELINES (INTERNATIONAL CO-OPERATION ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF VETERINARY MEDICINAL PRODUCTS)

7.1.3.2

GOOD MANUFACTURING PRACTICE (GMP) STANDARDS – PIC/S GUIDE (PE 009 SERIES)

7.1.3.3

CODEX ALIMENTARIUS STANDARDS FOR VETERINARY DRUG RESIDUES (CXM 2 – MAXIMUM RESIDUE LIMITS)

7.2

SUSTAINABILITY INITIATIVES

7.2.1

ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET

7.2.1.1

VIRBAC – ECO-PACK TO REDUCE SINGLE-USE PLASTIC IN VETERINARY PRODUCTS

7.2.1.2

BOEHRINGER INGELHEIM ANIMAL HEALTH – RENEWABLE ENERGY-POWERED MANUFACTURING

7.2.1.3

BOEHRINGER INGELHEIM – RECYCLABLE VETERINARY DELIVERY DEVICE (ASERVO, EQUIHALER)

7.3

CERTIFICATIONS, LABELING, ECO-STANDARDS

CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

Identify unmet needs driving innovation in veterinary pharmaceuticals for enhanced market profitability.

102

8.1

DECISION-MAKING PROCESS

8.2

KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA

8.2.1

KEY STAKEHOLDERS IN BUYING PROCESS

8.2.2

BUYING CRITERIA

8.3

ADOPTION BARRIERS AND INTERNAL CHALLENGES

8.4

UNMET NEEDS IN VARIOUS END-USE SETTINGS

8.5

MARKET PROFITABILITY

8.5.1

PRODUCT INNOVATION AND DIFFERENTIATION

8.5.2

EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING

8.5.3

OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY

VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 21 Data Tables

107

9.1

INTRODUCTION

9.1.1

VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

9.2

DRUGS

9.2.1

ANTI-BACTERIAL DRUGS

9.2.1.1

ROUTINE USE IN LIVESTOCK AND COMPANION ANIMALS UNDERPINS STRONG MARKET SHARE AND STEADY GROWTH

9.2.2

ANTI-FUNGAL DRUGS

9.2.2.1

LIMITED APPROVALS AND OFF-LABEL SYSTEMIC USE RESULT IN SMALLER BUT CLINICALLY ESSENTIAL SEGMENT

9.2.3

ANTI-VIRAL DRUGS

9.2.3.1

LOW CURRENT PENETRATION BUT RISING RESEARCH INTEREST DRIVEN BY OUTBREAK RESPONSE AND TARGETED THERAPIES

9.2.4

ANTI-INFLAMMATORY DRUGS

9.2.4.1

RISING SURGICAL VOLUMES AND CHRONIC PAIN MANAGEMENT DRIVE STABLE DOUBLE-DIGIT MARKET SHARE

9.2.5

ANTI-PARASITIC DRUGS

9.2.5.1

HIGH PARASITIC BURDEN AND PREVENTIVE CARE PRACTICES SUSTAIN MARKET SHARE AND STRONG GROWTH TRAJECTORY

9.2.6

ANTI-CANCER DRUGS

9.2.6.1

INCREASING PET ONCOLOGY AWARENESS AND ADVANCED THERAPEUTICS TO FUEL GROWTH FROM SMALL BASE

9.2.7

CARDIOVASCULAR AND RENAL DRUGS

9.2.7.1

RISING DIAGNOSIS OF CHRONIC HEART AND KIDNEY DISORDERS SUPPORTS STEADY MID-SINGLE-DIGIT MARKET SHARE

9.2.8

GASTROINTESTINAL DRUGS

9.2.8.1

HIGH INCIDENCE OF DIGESTIVE DISORDERS AND DIETARY TRANSITIONS DRIVE SUSTAINED DEMAND

9.2.9

OTHER DRUGS

9.3

MONOCLONAL ANTIBODIES

9.3.1

TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND

9.4

IMMUNOMODULATORS

9.4.1

INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE

9.5

MEDICATED FEED ADDITIVES

9.5.1

AMINO ACIDS

9.5.1.1

PROTEIN OPTIMIZATION AND FEED COST EFFICIENCY TO DRIVE DEMAND

9.5.2

ENZYMES

9.5.2.1

IMPROVED NUTRIENT DIGESTIBILITY AND COST OPTIMIZATION TO SUPPORT STEADY ADOPTION

9.5.3

VITAMINS AND MINERALS

9.5.3.1

ESSENTIAL MICRONUTRIENT SUPPLEMENTATION ENSURES LARGEST MARKET SHARE

9.5.4

OTHER MEDICATED FEED ADDITIVES

VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 5 Data Tables

128

10.1

INTRODUCTION

10.2

ORAL

10.2.1

EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS

10.3

PARENTERAL

10.3.1

RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN CRITICAL CARE AND PRODUCTION SETTINGS

10.4

TOPICAL

10.4.1

RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED, NON-INVASIVE TREATMENTS

10.5

OTHER ROUTES OF ADMINISTRATION

VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 6 Data Tables

134

11.1

INTRODUCTION

11.2

SOLID

11.2.1

DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS

11.3

LIQUID

11.3.1

RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS

11.4

SEMI-SOLID

11.4.1

RISING DERMATOLOGY CASES AND INCREASING COMPANION ANIMAL CARE EXPENDITURE

11.5

AEROSOL/SPRAY

11.5.1

CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK

11.6

PREMIX FORMULATIONS

11.6.1

DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET

VETERINARY PHARMACEUTICALS MARKET, BY INDICATION

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables

141

12.1

INTRODUCTION

12.2

INFECTIOUS DISEASES

12.2.1

ZOONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET

12.3

DERMATOLOGICAL DISEASES

12.3.1

RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET

12.4

PAIN MANAGEMENT

12.4.1

RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET

12.5

CARDIOVASCULAR AND RENAL DISEASES

12.5.1

INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET

12.6

GASTROINTESTINAL DISEASES

12.6.1

HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET

12.7

OTHER INDICATIONS

VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 13 Data Tables

149

13.1

INTRODUCTION

13.2

COMPANION ANIMALS

13.2.1

DOGS

13.2.1.1

INCREASING POPULATION AND ADOPTION OF DOGS TO DRIVE MARKET

13.2.2

CATS

13.2.2.1

EMERGING TRENDS IN FELINE PHARMACEUTICALS TO BOOST MARKET

13.2.3

HORSES

13.2.3.1

HIGHER RISK OF TRAUMATIC INJURIES IN HORSES TO DRIVE DEMAND FOR VETERINARY PHARMACEUTICAL PRODUCTS

13.2.4

OTHER COMPANION ANIMALS

13.3

LIVESTOCK ANIMALS

13.3.1

CATTLE

13.3.1.1

ECONOMIC IMPORTANCE OF DAIRY AND BEEF CATTLE TO DRIVE GROWTH

13.3.2

SWINE

13.3.2.1

GROWING SURGICAL VOLUME FOR ACUTE CONDITIONS IN SWINE TO DRIVE MARKET

13.3.3

POULTRY

13.3.3.1

GROWING FOCUS ON INFECTION PREVENTION AND FLOCK HEALTH MANAGEMENT TO DRIVE MARKET

13.3.4

OTHER LIVESTOCK ANIMALS

VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 5 Data Tables

169

14.1

INTRODUCTION

14.2

VETERINARY HOSPITAL PHARMACIES

14.2.1

HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET

14.3

RETAIL PHARMACIES

14.3.1

RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS

14.4

ONLINE PHARMACIES

14.4.1

CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH

14.5

DIRECT SALES

14.5.1

DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS

VETERINARY PHARMACEUTICALS MARKET, BY END USER

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 5 Data Tables

177

15.1

INTRODUCTION

15.2

VETERINARY HOSPITALS & CLINICS

15.2.1

FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS

15.3

LIVESTOCK FARMS

15.3.1

GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE

15.4

HOME CARE SETTINGS

15.4.1

RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH

15.5

OTHER END USERS

VETERINARY PHARMACEUTICALS MARKET, BY REGION

Comprehensive coverage of 8 Regions with country-level deep-dive of 18 Countries | 338 Data Tables.

183

16.1

INTRODUCTION

16.2

NORTH AMERICA

16.2.1

MACROECONOMIC OUTLOOK FOR NORTH AMERICA

16.2.2

NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

16.2.3

16.2.3.1

SURGE IN ANIMAL HEALTHCARE EXPENDITURE TO BOOST MARKET

16.2.4

CANADA

16.2.4.1

GROWING PET POPULATION AND ADVANCED VETERINARY SERVICES TO DRIVE MARKET

16.3

EUROPE

16.3.1

MACROECONOMIC OUTLOOK FOR EUROPE

16.3.2

EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

16.3.3

GERMANY

16.3.3.1

INCREASED FOCUS ON ANIMAL WELFARE TO DRIVE DEMAND FOR VETERINARY PHARMACEUTICAL PRODUCTS

16.3.4

16.3.4.1

INCREASING PET OWNERSHIP TO PROPEL MARKET

16.3.5

FRANCE

16.3.5.1

HIGH STANDARDS OF VETERINARY CARE TO PROVIDE ATTRACTIVE GROWTH OPPORTUNITIES FOR MARKET PLAYERS

16.3.6

ITALY

16.3.6.1

GROWING PET OWNER AWARENESS AND INCREASING LIVESTOCK POPULATION TO DRIVE MARKET

16.3.7

SPAIN

16.3.7.1

INCREASING AWARENESS OF ANIMAL HEALTH TO DRIVE MARKET

16.3.8

REST OF EUROPE

16.4

ASIA PACIFIC

16.4.1

MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

16.4.2

ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

16.4.3

JAPAN

16.4.3.1

SURGE IN PET CARE EXPENDITURE AND GROWING ADOPTION OF COMPANION ANIMALS TO DRIVE MARKET

16.4.4

CHINA

16.4.4.1

INCREASING ANIMAL HEALTHCARE EXPENDITURE AND ADVANCEMENTS IN VETERINARY MEDICINES TO DRIVE MARKET

16.4.5

INDIA

16.4.5.1

INCREASING LIVESTOCK POPULATION TO PROPEL MARKET GROWTH

16.4.6

AUSTRALIA

16.4.6.1

GROWING COMPANION ANIMAL OWNERSHIP AND RISE IN ANIMAL HEALTH AWARENESS TO SUPPORT MARKET GROWTH

16.4.7

SOUTH KOREA

16.4.7.1

GROWING PET OWNERSHIP AND ADVANCEMENTS IN VETERINARY MEDICINE TO FAVOR MARKET GROWTH

16.4.8

PHILIPPINES

16.4.8.1

TOURISM-LINKED PET CULTURE AND VETERINARY ADVANCEMENTS TO FUEL MARKET

16.4.9

REST OF ASIA PACIFIC

16.5

LATIN AMERICA

16.5.1

MACROECONOMIC OUTLOOK FOR LATIN AMERICA

16.5.2

LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

16.5.3

BRAZIL

16.5.3.1

GROWING PET POPULATION AND RISING DISPOSABLE INCOMES TO DRIVE MARKET

16.5.4

MEXICO

16.5.4.1

ROBUST LIVESTOCK BASE AND GROWING COMPANION ANIMAL CARE TO DRIVE MARKET

16.5.5

REST OF LATIN AMERICA

16.6

MIDDLE EAST & AFRICA

16.6.1

MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

16.6.2

MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

16.7

GCC COUNTRIES

16.7.1

KINGDOM OF SAUDI ARABIA (KSA)

16.7.1.1

VISION 2030 INVESTMENTS TO DRIVE MARKET

16.7.2

UNITED ARAB EMIRATES (UAE)

16.7.2.1

INCREASING ADOPTION OF ADVANCED DIAGNOSTIC TECHNOLOGIES TO CONTRIBUTE TO MARKET GROWTH

16.7.3

REST OF GCC COUNTRIES

16.7.4

REST OF MIDDLE EAST & AFRICA

COMPETITIVE LANDSCAPE

Discover market leaders and emerging competitors shaping the veterinary pharmaceuticals landscape.

357

17.1

INTRODUCTION

17.1.1

KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026

17.2

REVENUE ANALYSIS, 2023–2025

17.3

MARKET SHARE ANALYSIS, 2025

17.3.1

US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025

17.3.2

EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025

17.4

PRODUCT/BRAND COMPARISON

17.5

COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025

17.5.1

STARS

17.5.2

EMERGING LEADERS

17.5.3

PERVASIVE PLAYERS

17.5.4

PARTICIPANTS

17.5.5

COMPANY FOOTPRINT: KEY PLAYERS, 2025

17.5.5.1

COMPANY FOOTPRINT

17.5.5.2

REGION FOOTPRINT

17.5.5.3

PRODUCT TYPE FOOTPRINT

17.5.5.4

ROUTE OF ADMINISTRATION FOOTPRINT

17.5.5.5

INDICATION FOOTPRINT

17.5.5.6

END USER FOOTPRINT

17.6

COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025

17.6.1

PROGRESSIVE COMPANIES

17.6.2

RESPONSIVE COMPANIES

17.6.3

DYNAMIC COMPANIES

17.6.4

STARTING BLOCKS

17.6.5

COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025

17.6.5.1

DETAILED LIST OF KEY STARTUPS/SMES

17.6.5.2

COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

17.7

COMPANY VALUATION AND FINANCIAL METRICS

17.8

COMPETITIVE SCENARIO

17.8.1

PRODUCT LAUNCHES & APPROVALS

17.8.2

DEALS

17.8.3

EXPANSIONS

17.8.4

OTHER DEVELOPMENTS

COMPANY PROFILES

In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)

380

18.1

KEY PLAYERS

18.1.1

ZOETIS INC.

18.1.1.1

BUSINESS OVERVIEW

18.1.1.2

PRODUCTS OFFERED

18.1.1.3

RECENT DEVELOPMENTS

18.1.1.3.1

PRODUCT LAUNCHES & APPROVALS

18.1.1.3.2

EXPANSIONS

18.1.1.3.3

OTHER DEVELOPMENTS

18.1.1.4

MNM VIEW

18.1.1.4.1

RIGHT TO WIN

18.1.1.4.2

STRATEGIC CHOICES

18.1.1.4.3

WEAKNESSES AND COMPETITIVE THREATS

18.1.2

MERCK & CO., INC

18.1.3

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

18.1.4

ELANCO ANIMAL HEALTH INCORPORATED

18.1.5

VIRBAC

18.1.6

CEVA

18.1.7

VETOQUINOL

18.1.8

DECHRA PHARMACEUTICALS PLC

18.1.9

NORBROOK

18.1.10

BIMEDA CORPORATE

18.1.11

HESTER BIOSCIENCES LIMITED

18.1.12

INDIAN IMMUNOLOGICALS LTD.

18.1.13

ANIMALCARE GROUP PLC

18.1.14

KYORITSU SEIYAKU CORPORATION

18.1.15

CALIER

18.2

OTHER PLAYERS

18.2.1

DOPHARMA

18.2.2

PHARMGATE ANIMAL HEALTH

18.2.3

BIOVETA, A.S.

18.2.4

NEXTMUNE

18.2.5

TRIVIUMVET

18.2.6

DOMES PHARMA

18.2.7

UNIVET LIMITED

18.2.8

CENAVISA, S.L.

18.2.9

FATRO S.P.A.

18.2.10

CHANELLE PHARMA

RESEARCH METHODOLOGY

457

19.1

RESEARCH DATA

19.1.1

SECONDARY DATA

19.1.1.1

KEY DATA FROM SECONDARY SOURCES

19.1.2

PRIMARY DATA

19.1.2.1

KEY DATA FROM PRIMARY SOURCES

19.1.2.2

KEY INDUSTRY INSIGHTS

19.1.2.3

KEY INDUSTRY INSIGHTS

19.2

MARKET SIZE ESTIMATION

19.3

GROWTH FORECAST

19.3.1

KEY INDUSTRY INSIGHTS

19.4

MARKET BREAKDOWN AND DATA TRIANGULATION

19.5

RESEARCH ASSUMPTIONS

19.6

RESEARCH LIMITATIONS

19.7

RISK ASSESSMENT

APPENDIX

471

20.1

DISCUSSION GUIDE

20.2

KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

20.3

CUSTOMIZATION OPTIONS

20.3.1

PRODUCT ANALYSIS

20.3.2

US END USER ANALYSIS

20.3.3

GEOGRAPHIC ANALYSIS

20.3.4

Methodology

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the Veterinary Pharmaceuticals Market. It was also used to obtain important information about the key players, market classification, and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the Veterinary Pharmaceuticals Markets. Primary sources from the demand side include healthcare professionals from hospitals, ambulatory surgical centers, long-term care facilities, diagnostic imaging centers, outpatient clinics, and other end users.

A breakdown of the primary respondents is provided below:

Veterinary Pharmaceuticals Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other Designations include sales managers, marketing managers, and product managers.
Note 3: Tiers are defined based on a company’s total revenue as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the veterinary pharmaceuticals market was determined through data triangulation across three approaches, as outlined below. After each approach, the weighted average of the three was calculated based on the level of assumptions used in each.

Veterinary Pharmaceuticals Market : Top-Down and Bottom-Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed where applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in the market engineering process.

Market Definition

The veterinary pharmaceuticals market comprises medicinal products used to prevent, control, and treat diseases in animals, excluding vaccines. It includes therapeutic drug classes such as anti-infectives (antibacterials, antivirals, antifungals, antiparasitic), anti-inflammatory drugs, hormonal therapies, dermatological drugs, cardiovascular drugs, gastrointestinal agents, and other prescription and over-the-counter pharmaceuticals. These products address indications including infectious diseases, dermatological disorders, reproductive health, metabolic diseases, and pain management, among others. The market covers both companion and livestock animals and is supplied through veterinary hospitals, clinics, pharmacies, and animal health distribution channels globally.

Key Stakeholders

Veterinary Pharmaceutical Manufacturers (Branded & Generic Drug Manufacturers)
Veterinary Generic Drug Manufacturers
Veterinary Compounding Pharmacies
Veterinary Contract Manufacturing Organizations (CMOs)
Active Pharmaceutical Ingredient (API) Suppliers for Animal Health
Veterinary Hospitals and Specialty Veterinary Clinics
General Veterinary Practitioners
Livestock Farm Owners and Commercial Farm Operators
Companion Animal Owners (Pet Owners)
Veterinary Group Purchasing Organizations (GPOs)
Animal Health Distributors and Wholesalers
Veterinary Pharmacy Chains (Retail & Online)
E-Pharmacy Platforms for Animal Medicines
Regulatory Authorities (e.g., FDA-CVM, EMA, CDSCO, VMD)
Animal Health Contract Research Organizations (CROs)
Academic and Veterinary Research Institutes
Animal Health Insurance Providers (Pet Insurance Companies)
Feedlot and Integrated Livestock Production Companies
Animal Welfare Organizations

Report Objectives

To define, describe, and forecast the veterinary pharmaceuticals market, product type, route of administration, formulation type, indication, animal type, distribution channel, end user, and region
To provide detailed information about the key factors influencing market growth, such as drivers, restraints, opportunities, challenges, and industry trends
To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis,
patent analysis, impact of AI, trends/disruption impacting customers’ business in the market, and the impact of the 2025 US tariff on the market.
To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall veterinary pharmaceuticals market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies.
To strategically analyze the veterinary pharmaceuticals market in five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
To track and analyze competitive developments such as product launches and approvals, acquisitions, partnerships, collaborations, and expansions in the veterinary pharmaceuticals market

Available customizations:

Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:

Competitive Landscape Assesment

Market share analysis for the North America and Europe region, which provides market shares of the top 3–5 key players in the veterinary pharmaceuticals market
Competitive leadership mapping for established players in the US

Regional Analysis

Further breakdown of the Rest of European veterinary pharmaceuticals market into Austria, Finland, the Netherlands, Switzerland, and others
Further breakdown of the Rest of Latin American veterinary pharmaceuticals market into Argentina, Colombia, Chile, and others

Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User�Global Forecast to 2031

OVERVIEW

KEY TAKEAWAYS

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

MARKET DYNAMICS

Driver: Rising companion animal ownership and pet humanization

Restraint: Growing concerns over antimicrobial resistance (AMR)

Opportunity: Rising demand for parasiticides and dermatology products

Challenge: Monitoring drug residues in food-producing animals

VETERINARY PHARMACEUTICALS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

MARKET ECOSYSTEM

MARKET SEGMENTS

By Product Type

By Indications

REGION

By Region

VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX

KEY MARKET PLAYERS

MARKET SCOPE

WHAT IS IN IT FOR YOU: VETERINARY PHARMACEUTICALS MARKET REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

RECENT DEVELOPMENTS

Table of Contents

Methodology

Secondary Research

Primary Research

Market Size Estimation

Veterinary Pharmaceuticals Market : Top-Down and Bottom-Up Approach

Data Triangulation

Market Definition

Key Stakeholders

Report Objectives

Available customizations:

Competitive Landscape Assesment

Regional Analysis

Company Information

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Personalize This Research

Let Us Help You

TESTIMONIALS

JAYANT RAJPUROHIT

SFI Health,

BEATRIZ DE LA CALLE

Qualicaps,

Bob Williams,

Bracco Diagnostics Inc.,

Cody Coonradt,

3M Health Information Systems,

Growth opportunities and latent adjacency in Veterinary Pharmaceuticals Market